Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2011 | 1 |
2014 | 2 |
2017 | 2 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Metabolic PET Imaging in Oncology.
AJR Am J Roentgenol. 2017 Aug;209(2):270-276. doi: 10.2214/AJR.17.18112. Epub 2017 May 2.
AJR Am J Roentgenol. 2017.
PMID: 28463521
Review.
Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy.
Bingham PM, Stuart SD, Zachar Z.
Bingham PM, et al. Among authors: zachar z.
Expert Rev Clin Pharmacol. 2014 Nov;7(6):837-46. doi: 10.1586/17512433.2014.966816. Epub 2014 Oct 4.
Expert Rev Clin Pharmacol. 2014.
PMID: 25284345
Review.
Item in Clipboard
Toward a Unifying Hypothesis for Redesigned Lipid Catabolism as a Clinical Target in Advanced, Treatment-Resistant Carcinomas.
Bingham PM, Zachar Z.
Bingham PM, et al. Among authors: zachar z.
Int J Mol Sci. 2023 Sep 21;24(18):14365. doi: 10.3390/ijms241814365.
Int J Mol Sci. 2023.
PMID: 37762668
Free PMC article.
Review.
Item in Clipboard
Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613.
Guardado Rivas MO, Stuart SD, Thach D, Dahan M, Shorr R, Zachar Z, Bingham PM.
Guardado Rivas MO, et al. Among authors: zachar z.
PLoS One. 2022 Jun 8;17(6):e0269620. doi: 10.1371/journal.pone.0269620. eCollection 2022.
PLoS One. 2022.
PMID: 35675354
Free PMC article.
Item in Clipboard
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo.
Zachar Z, Marecek J, Maturo C, Gupta S, Stuart SD, Howell K, Schauble A, Lem J, Piramzadian A, Karnik S, Lee K, Rodriguez R, Shorr R, Bingham PM.
Zachar Z, et al.
J Mol Med (Berl). 2011 Nov;89(11):1137-48. doi: 10.1007/s00109-011-0785-8. Epub 2011 Jul 19.
J Mol Med (Berl). 2011.
PMID: 21769686
Item in Clipboard
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process.
Stuart SD, Schauble A, Gupta S, Kennedy AD, Keppler BR, Bingham PM, Zachar Z.
Stuart SD, et al. Among authors: zachar z.
Cancer Metab. 2014 Mar 10;2(1):4. doi: 10.1186/2049-3002-2-4.
Cancer Metab. 2014.
PMID: 24612826
Free PMC article.
Item in Clipboard
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B.
Alistar A, et al. Among authors: zachar z.
Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. Epub 2017 May 8.
Lancet Oncol. 2017.
PMID: 28495639
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite